Trial Profile
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 16 Jun 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 16 Jun 2023 Planned primary completion date changed from 20 May 2023 to 1 May 2024.
- 13 Dec 2022 Results reporting MRD negativity and survival outcomes presented at the 64th American Society of Hematology Annual Meeting and Exposition